BGR-34 for Diabetes: Where is the evidence?

An herbal drug, developed jointly by the National Botanical Research Institute (NBRI) and the Central Institute of Medicinal and Aromatic Plants (CIMAP), branded as BGR-34, has been commercialized by Delhi-based Aimil Pharmaceuticals and marketed as a potentially side-effect free treatment for diabetes. However, a search for publications outlining trials conducted to support the claimed “67%…

Rate this:

If Carbapenems Go, Can Colistin be Far Behind?

I wrote about the disaster-in-the-making discovery of transmissible resistance to colistin, a last resort antibiotic, when the Lancet Infectious Diseases published a paper based on data coming out from surveillance in China. At that point of time, the isolation of the transmissible gene providing resistance (mcr1 gene) gained a lot of attention. Maryn McKenna’s blog post went…

Rate this:

What's your p-value?

Ronald Fisher and Some Thoughts on the p-Value

One of the most discussed, debated and controversial issues in medical research is the p-value. I came across Ronald Fisher’s take on this matter in his work, Statistical Methods for the Research Worker, 1925 (the text of this work has been made available online by Christopher D. Green of the York University): “The value for…

Rate this:

06_02_15SocializedMedicine

EqualHealth Opens up Social Medicine Course

From the EqualHealth website: Beyond the Biological Basis of Disease: The Social and Economic Causation of Illness is offered by EqualHealth in collaboration with SocMed, an organization that advocates for and implements global health curricula founded on the study of social medicine. EqualHealth is excited to expand upon SocMed’s well-established curriculum to focus on the specific…

Rate this: